V
VANDA PHARMACEUTICALS INC
NASDAQ: VNDA (Vanda Pharmaceuticals Inc.)
Kemas kini terakhir: 23 minit lalu4.49
-0.09 (-1.97%)
| Penutupan Terdahulu | 4.58 |
| Buka | 4.53 |
| Jumlah Dagangan | 268,399 |
| Purata Dagangan (3B) | 549,539 |
| Modal Pasaran | 264,615,888 |
| Harga / Pendapatan (P/E Ke hadapan) | 30.30 |
| Harga / Jualan (P/S) | 1.33 |
| Harga / Buku (P/B) | 0.530 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2025 - 4 Aug 2025 |
| Margin Keuntungan | -21.98% |
| Margin Operasi (TTM) | -81.99% |
| EPS Cair (TTM) | -0.760 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.30% |
| Nisbah Semasa (MRQ) | 3.92 |
| Aliran Tunai Operasi (OCF TTM) | -56.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -41.71 M |
| Pulangan Atas Aset (ROA TTM) | -7.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Vanda Pharmaceuticals Inc. | Menurun | Menaik |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.40 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.16% |
| % Dimiliki oleh Institusi | 77.63% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tang Capital Management Llc | 31 Mar 2025 | 2,353,307 |
| Connor, Clark & Lunn Investment Management Ltd. | 31 Mar 2025 | 929,644 |
| Krensavage Asset Management, Llc | 31 Mar 2025 | 754,381 |
| Federated Hermes, Inc. | 31 Mar 2025 | 726,915 |
| Prudential Financial Inc | 31 Mar 2025 | 710,710 |
| Goldman Sachs Group Inc | 31 Mar 2025 | 693,852 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 20.00 (HC Wainwright & Co., 345.43%) | Beli |
| Median | 16.50 (267.48%) | |
| Rendah | 13.00 (Cantor Fitzgerald, 189.53%) | Beli |
| Purata | 16.50 (267.48%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 4.15 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 13.00 (189.53%) | Beli | 3.92 |
| HC Wainwright & Co. | 07 May 2025 | 20.00 (345.43%) | Beli | 4.38 |
| 01 Apr 2025 | 20.00 (345.43%) | Beli | 4.50 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CHROUSOS PHAEDRA | 4.39 | - | 59,225 | 259,998 |
| DUGAN RICHARD W | 4.39 | - | 59,225 | 259,998 |
| HONORE TAGE | 4.39 | - | 59,225 | 259,998 |
| MITCHELL STEPHEN RAY | 4.39 | - | 59,225 | 259,998 |
| WARD ANNE SEMPOWSKI | 4.39 | - | 59,225 | 259,998 |
| Jumlah Keseluruhan Kuantiti Bersih | 296,125 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,299,989 | |||
| Purata Pembelian Keseluruhan ($) | 4.39 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WARD ANNE SEMPOWSKI | Pengarah | 05 Jun 2025 | Diperolehi (+) | 59,225 | 4.39 | 259,998 |
| HONORE TAGE | Pengarah | 05 Jun 2025 | Diperolehi (+) | 59,225 | 4.39 | 259,998 |
| DUGAN RICHARD W | Pengarah | 05 Jun 2025 | Diperolehi (+) | 59,225 | 4.39 | 259,998 |
| CHROUSOS PHAEDRA | Pengarah | 05 Jun 2025 | Diperolehi (+) | 59,225 | 4.39 | 259,998 |
| MITCHELL STEPHEN RAY | Pengarah | 05 Jun 2025 | Diperolehi (+) | 59,225 | 4.39 | 259,998 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Jun 2025 | Pengumuman | Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S |
| 16 May 2025 | Pengumuman | Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 |
| 07 May 2025 | Pengumuman | Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results |
| 05 May 2025 | Pengumuman | Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 |
| 02 May 2025 | Pengumuman | Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 |
| 23 Apr 2025 | Pengumuman | FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA |
| 07 Apr 2025 | Pengumuman | Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting |
| 31 Mar 2025 | Pengumuman | Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |